Skip to main navigation

The link is opening in a new window or tab that may or may not accessible Opens an external site Opens an external site in a new window

Pre-Header Contact

800-449-3353 | custserv@rockwellmed.com |

Footer Socials

Pre-Header Menu

Careers | Contact Us

Client Header Links

Home
Our Company
Our Therapeutic Focus
Our Technology
Hemodialysis Concentrates
Investors

Investor Relations

Press Releases

Main navigation

Investor Home
Press Releases
Events & Presentations
Corporate Governance
Management
Annual Meeting
Financial Information
Stock Information
Investor FAQs
Contact Us
Shareholder Tools

Press Releases

Year

Feb 09, 2021

Rockwell Medical Announces U.S. Availability of Triferic® AVNU for Replacement of Iron and Maintenance of Hemoglobin in Patients on Hemodialysis

PDF Version

Feb 01, 2021

Rockwell Medical Announces Submission of Triferic® New Drug Application in South Korea by Partner, Jeil Pharmaceutical Co., Ltd.

PDF Version

Jan 13, 2021

Rockwell Medical Announces Dosing of First Patient in Pivotal Triferic® Phase 3 Trial by Partner, Wanbang Biopharmaceuticals, in China

PDF Version

Jan 05, 2021

Rockwell Medical, Inc. to Present at H.C. Wainwright BioConnect 2021 Conference

PDF Version

Pagination

First page
Previous page
Page 1
Current page 2

Shareholder Tools

Snapshot

Email Alerts

RSS News Feeds

Have any questions?

Phone 248 432-1997

invest@rockwellmed.com

Client Header Links

Home
Our Company
Our Therapeutic Focus
Our Technology
Hemodialysis Concentrates
Investors
Contact

Footer Socials